POPULARITY
13 episodes with Recurrence
7 episodes with Recurrence
6 episodes with Recurrence
9 episodes with Recurrence
5 episodes with Recurrence
7 episodes with Recurrence
6 episodes with Recurrence
3 episodes with Recurrence
6 episodes with Recurrence
8 episodes with Recurrence
5 episodes with Recurrence
4 episodes with Recurrence
6 episodes with Recurrence
8 episodes with Recurrence
8 episodes with Recurrence
6 episodes with Recurrence
4 episodes with Recurrence
6 episodes with Recurrence
4 episodes with Recurrence
4 episodes with Recurrence
5 episodes with Recurrence
6 episodes with Recurrence
3 episodes with Recurrence
9 episodes with Recurrence
3 episodes with Recurrence
4 episodes with Recurrence
4 episodes with Recurrence
6 episodes with Recurrence
4 episodes with Recurrence
8 episodes with Recurrence
4 episodes with Recurrence
3 episodes with Recurrence
10 episodes with Recurrence
4 episodes with Recurrence
3 episodes with Recurrence
3 episodes with Recurrence
In this first part of a special two-episode series of TOGA's Conversations in Lung Cancer Research podcast, A/Prof Deme Karikios, a Medical Oncologist at the Nepean Hospital in NSW, is joined by Prof Ken O'Byrne, a Consultant and Professor in Medical Oncology at the Princess Alexandra Hospital and the Queensland University of Technology, and A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide. The panel discusses the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia, including the removal of 'once in a life time' rule. This major structural shift moves oncology prescribing away from rigid, indication-specific silos and toward clinician discretion guided by a patient's individual biology and the best available clinical evidence. This episode also covers what this means for advanced and metastatic thoracic malignancies, the biological rationale behind single versus doublet immunotherapy, and the practicalities of managing these clinical decisions. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. Resource Links: CM816 https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 CM9LA https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/abstract CM227-https://www.nejm.org/doi/full/10.1056/NEJMoa1910231 CM227 was a clinical trial that examined ipi/nivo, nivo alone or chemotherapy in pts with NSCLC with PD-L1 expression level of 1% (00:00) Welcome and Acknowledgement (02:00) New PBS Listing Explained (04:18) Defining Advanced and Sensitive (07:18) Dual vs Single Immunotherapy (12:27) Early Stage and Recurrence (14:26) Duration Stopping and Restarting (20:57) Other Thoracic Cancers (23:55) System Impact and Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
BUFFALO, NY – June 15, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 5, 2026, titled “A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.” The study was led by first author Emily Bivens and corresponding author Mayumi Nakagawa from the University of Arkansas for Medical Sciences, Little Rock. Head and neck squamous cell carcinoma (HNSCC) remains a major clinical challenge. Even after surgery, radiation, and chemotherapy successfully eliminate detectable disease, many patients experience recurrence within the following years. Researchers have therefore been exploring whether immunotherapy-based approaches can help strengthen anti-tumor immune responses and reduce the risk of cancer returning. In this study, investigators evaluated PepCan, an experimental therapeutic vaccine designed to stimulate immune responses against human papillomavirus type 16 (HPV 16). Unlike preventive HPV vaccines that aim to stop infection before it occurs, therapeutic vaccines are intended to activate the immune system against existing HPV-related disease. PepCan contains four HPV 16 E6 peptides combined with a Candida-derived immune-stimulating adjuvant. Full press release - https://www.oncotarget.net/2026/06/15/hpv-therapeutic-vaccine-shows-safety-but-uncertain-benefit-in-preventing-head-and-neck-cancer-recurrence/ DOI - https://doi.org/10.18632/oncotarget.28892 Correspondence to - Mayumi Nakagawa - mnakagawa@uams.edu Abstract video - https://www.youtube.com/watch?v=oh0MNrrPGhw Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28892 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, human papillomavirus, head and neck cancer, therapeutic vaccine, adjuvant, clinical trial To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Dr. Liao breaks down Lions injuries The Daily DLP welcomes Dr. Jimmy Liao to the show to talk about the Lions injuries and recoveries. The biggest name is Kerby Joseph, as the safety is dealing with a troublesome knee injury. Dr. Liao breaks down what options the Lions have with the All-Pro, noting that holding him out from the offseason workouts is medically necessary. Brian Branch's Achilles and what defense demands Brian Branch tore his Achilles on December 4, 2025. A comparison was made to another high-profile Achilles tear, San Francisco TE George Kittle, on January 11. The positions are different. Defense is reactive. The secondary lives in backpedals and sudden bursts. That movement is the top mechanism for Achilles injury. It can slow the return for a defensive back compared with an offensive player who can script his steps. Recent rehab clips showed light treadmill jogging. No hard sprinting. No jumping. No cutting. He is roughly six months out and not ahead of schedule on visible benchmarks. The earlier expectation hovered around midseason. There is no clear evidence to move that up. Sam LaPorta's back: progress now, recurrence is the concern Sam LaPorta appeared at OTAs. He caught passes. He is not full go, but the trend is positive. A herniated disc can flare with accumulated contact. Blocking can hyperextend the back. Last season's issue was not a single moment. It built over time. There is a good chance he is ready for Week 1. The question is durability over months, not days. Recurrence risk sits in the background and will only be answered by workload. Depth chart ripple effects: OL Lisfranc, ACL note, and return-game risk An offensive lineman, Ben Bartch, is recovering from Lisfranc surgery. He has not appeared in the first two weeks of OTAs. Lisfranc injuries live in a small, tricky part of the midfoot. Outcomes can be uncertain, especially for a big body that must anchor and drive. The Lions guaranteed $330,000 on his one-year deal, a sign of confidence at signing, but the absence raises flags until he is on the field. Kendrick Law suffered an ACL tear. Standard ACL recoveries are reliable. Barring complications, the expectation is a full return for 2026 OTAs. Safety Dan Jackson has been present in team photos during OTAs. Last year's leg issue lacked detail, but current participation eases concern. Kickoff changes have pushed return rates above 70 percent. Depth at returner matters. The play remains risky for the returner, even as it gets safer for blockers and coverage. Recent examples include a neck scare for Kalif Raymond and a fractured ankle for James Houston on a high-speed collision. Minicamp next week will sharpen clarity across the Detroit Lions depth chart. #detroitlions #lions #detroitlionspodcast #injuries #recoverytimeline #kerbyjoseph #brianbranch #samlaporta #georgekittle #lisfranc #benbartch #danjackson Learn more about your ad choices. Visit megaphone.fm/adchoices
What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancerhttps://ascopubs.org/doi/10.1200/JCO-25-01324 CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER:https://www.auajournals.org/doi/abs/10.1097/01.JU.0001191388.74345.c9.09 Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomyhttps://pubmed.ncbi.nlm.nih.gov/41843048/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
Get your FREE copy of "AZ Guide to Staying Cancer Free" here: https://www.cancerfreedomprogram.com/azcancerfree Your doctor says your labs look "normal" — but normal is not the same as optimal when you're trying to prevent a cancer recurrence. There are specific blood work markers that can give you an early warning sign that cancer is trying to come back — and most conventional doctors never even order them. So let me show you how it's done. Join the Cancer Freedom Program Apply HERE:https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast #cancerfighter #cancersurvivor #breastcancer #breastcancersurvivors #cancerrecovery #cancernutrition #mastectomy #tamoxifen #anastrozole #letrozole #exemestane PS - Whenever you're ready, here are the 2 best ways I can help you… Get your FREE copy of "AZ Guide to Staying Cancer Free" here: https://www.cancerfreedomprogram.com/azcancerfree Join the Cancer Freedom Program Apply HERE:https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast Let's Connect: Website: https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]
Where you are right now is not random—it's intentional, and it's revealing. In this episode, we dive into the affirmation “I am exactly where I'm supposed to be” and what it truly means to embody it, even when life doesn't look how you expected.I share how this affirmation has shaped my perspective, how to start seeing your current reality as valuable data instead of a setback, and why every situation—good or challenging—is working in your favor. We also break down the Law of Recurrence and how patterns in your life are not punishments, but teachers guiding you toward growth and alignment.If you're in a season that feels confusing, uncomfortable, or unclear, this episode will help you ground yourself, find power in the present moment, and start consciously shifting your reality. You'll walk away with a mindset that allows you to honor where you are while confidently creating what's next.✨ Theresa's Tools & Links :Affirmation Academywww.theresacesare.comMy Affirmation Card DeckJoin my newsletter for exclusive content & mindset toolsFollow me on Instagram:Personal page @iamtheresacesareAffirmation Babe @iamtheaffirmationbabeSupport the show
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Orforglipron for maintenance of body weight reduction - Nature Medicine2026. Discussion by:Guest:Joe Gonella, MD Resident - Abington Family Medicine Residency Program Jefferson Health2. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN) Lancet 2026. Discussion by: Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney Kimmel Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Survival and Recurrence with GLP-1 Receptor Agonists in Breast Cancer" – JAMA Network Open Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney Kimmel Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington4. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. NEJM 2026 Discussion by:Guest:Alex Sauer, MD Resident - Abington Family Medicine Residency ProgramJefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
Results from the OPTIMA trial suggest that people with early-stage hormone receptor-positive, HER2-negative breast cancer that seems to have a high risk of recurrence based on clinical features — like a high number of positive lymph nodes — may be able to safely skip chemotherapy if they have a low Prosigna risk of recurrence score. The findings were presented at the 2026 American Society of Clinical Oncology Annual Meeting. Iain MacPherson, professor of breast oncology at the University of Glasgow, was chief investigator of the study. Listen to the episode to hear Dr. MacPherson explain: the design and results of the OPTIMA study why he thinks the trial results are groundbreaking whether or not the results apply to men with this type of breast cancer
Sent us a text, you dicks!!IT'S BAAAAAAAAAAACK!!!!Your thought we were done with the sonnet episodes, didn't you?? NO, DEAR LISTENERS!!!! (After all, there are 154 of them!!!)And this time, we have our dear friend (and one of the top fans of the pod!!) Brian Linden with us!! Brian has chosen Sonnet 19 to perform and discuss, and we are tickled pink!!!Strap in and get ready!!!To send us an email - please do, we truly want to hear from you!!! - write us at: thebardcastyoudick@gmail.com To support us (by giving us money - we're a 501C3 Non-Profit - helllloooooo, tax deductible donation!!!) - per episode if you like! On Patreon, go here: https://www.patreon.com/user?u=35662364&fan_landing=trueOr on Paypal:https://www.paypal.com/donate/?hosted_button_id=8KTK7CATJSRYJWe also take cash! ;DTo visit our website, go here:https://www.thebardcastyoudick.comTo donate to an awesome charity, go here:https://actorsfund.org/help-our-entertainment-communiity-covid-19-emergency-reliefLike us? Don't have any extra moolah? We get it! Still love us and want to support us?? Then leave us a five-star rating AND a review wherever you get your podcasts!!Support the show
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Peter Carroll discusses biochemical recurrence. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41556]
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Peter Carroll discusses biochemical recurrence. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41556]
As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Peter Carroll discusses biochemical recurrence. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41556]
If you've ever laid awake at 2 or 3 in the morning wondering, "What if it comes back?"...this episode is for you. You are not alone, and you are not weak. In fact, nearly 6 in 10 cancer survivors report a fear of recurrence, and among young survivors that number jumps to 88%. It's the most common unmet need in survivorship...and almost no one talks about it openly. In this episode, Jen shares honestly where she is five years after her breast cancer diagnosis, what the fear of recurrence used to look like, and what's changed. Spoiler: the fear didn't disappear, but it's no longer running the show. What you'll learn in this episode: Why fear of recurrence is the most common (and most under-discussed) part of survivorship The research and statistics behind fear of recurrence in cancer survivors How to build your own trigger inventory so you stop getting ambushed The lifestyle, environmental, and spiritual shifts that helped Jen take her power back The one mindset shift that changes everything: from "What if it comes back?" to "If it comes back, here's what I do" Small, doable practices for when the fear shows up at 2 AM Why naming the fear out loud takes its power away How to choose the one person you can be totally honest with Key moments / chapter markers: (00:03) Why this thought is the most normal thing in the world (01:00) The research: 6 in 10 survivors carry this — and women carry it more (02:00) Building your trigger inventory: scans, anniversaries, Facebook memories, headlines (04:00) The work that changed everything — diet, environment, toxins, lifestyle (07:00) Becoming more spiritual and making peace with the unknown (09:30) Why breast cancer treatment in 2026 is night-and-day from 5–10 years ago (10:30) The shift: from "What if?" to "If it does, here's what I'll do" (11:30) Three small things to try when the fear shows up (14:00) The truth: the fear doesn't leave, but it stops being the loudest voice Connect with Jen: Community: Not Today Cancer — The Inner Circle GET BrocElite: Mara Labs supplements - Use code NotTodayCancer for 20% off Instagram: https://www.instagram.com/jendelvaux/ Email me: coachjennyd@gmail.com A gentle reminder: This episode is not medical advice and not a prescription. It's one survivor's story and the tools that have helped her. Always work with your own care team on what's right for you.
A casual night watching sports, a quick breast self-exam, and a lump that did not belong there. Faced with no insurance and four months of not knowing what to do, Felicia Kent walked into a neighborhood clinic, received a referral to The Rose, and heard the three words that changed everything: you have cancer. In this episode, she talks about choosing a treatment center, using research and strict adherence to medication to blunt chemo side effects, and learning to live with radiation fatigue, lymphedema, neuropathy, and a body that will never be the same. She also shares how faith, a determined daughter, an emotional support dog, and a calling to serve other survivors led her to start a nonprofit, finish her psychology degree, and focus on practical support and early mammograms in the African American community. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered 1. How did Felicia find her lump and what kept her from seeking help immediately? 2. How does someone without insurance get from a neighborhood clinic to The Rose for diagnostic care? 3. What does it feel like to hear “you have cancer,” and how did Felicia share that news with her family? 4. How did she choose a treatment center and manage chemo, surgery, and radiation side effects day to day? 5. What practical strategies helped her reduce chemo side effects like nausea, mouth sores, and nosebleeds? 6. How is she now supporting other patients through a nonprofit, church outreach, and peer-to-peer work? 7. Why are mindset, faith, and social support so critical during and after breast cancer treatment? 8. How is she raising awareness about mammograms and access within the African American community? 9. What long-term issues like lymphedema, neuropathy, and fear of recurrence does she still live with? 10. How does an emotional support dog, movement, and counseling help manage post-treatment anxiety? Timestamped Overview 00:00 Episode opens, Felicia’s story as an uninsured survivor who reached The Rose through a neighborhood clinic is introduced.01:20 Guest host Shannon McNair welcomes Felicia and asks how she discovered her lump and used self-exams.01:40 Felicia describes finding the lump by chance, lacking insurance, and remembering The Rose from boutique work.02:40 She visits a nearby clinic, receives an immediate referral to The Rose, and later credits the team with saving her life.04:30 Telling her sister, leaning on prayer, and deciding early to be a testimony for others facing cancer.06:20 What she wishes she had known about treatment, side effects, and why she followed medication instructions exactly.07:40 Lesser-discussed chemo and radiation side effects like mouth sores, nosebleeds, and fluid issues, and how she managed them.08:40 Birth of her nonprofit work, finishing a psychology degree during treatment, and pursuing community health worker training.09:50 Current advocacy: blogs, peer-to-peer conversations, holiday outreach, and small gifts to patients during treatment.10:40 Common questions she hears about insurance, alternatives, and staying positive through harsh treatments.12:10 How to support someone with cancer when you do not know what to say, including quiet presence and simple statements of love.13:40 Encouraging friends and family to show up with meals, learning, and practical help, while survivors learn to express what they need.16:30 Holiday and year-round programs for patients, including Christmas deliveries, Valentine outreach, and church-based change collections for donations to The Rose.19:10 Focus on education and early detection in the African American community, especially for younger women and those wary of treatment.20:30 Balancing chemo, lumpectomy, graduation, radiation, and then managing fluid buildup and other late effects.23:50 How an emotional support dog, daily walks, and therapy help manage anxiety and fear of recurrence after treatment.26:00 Decision to delay reconstruction, experiences losing a young niece and a church member to breast cancer, and why that fuels her advocacy.27:20 She reflects on cancer as an ongoing learning experience, the importance of mental health care, and continuing in support groups.See omnystudio.com/listener for privacy information.
Previous literature has demonstrated that an increased number of preoperative anterior shoulder instability episodes is associated with recurrent anterior shoulder instability after arthroscopic Bankart repair (ABR). However, a threshold for the number of preoperative instability episodes that increases the risk of recurrent anterior shoulder instability is not well established. A threshold of ≥2 preoperative anterior shoulder instability episodes best predicted recurrent anterior shoulder instability after ABR. Stratification beyond 1 versus ≥2 preoperative anterior shoulder instability episodes did not increase predictive ability. This finding may help surgeons to counsel patients and consider earlier surgical stabilization in those who have sustained anterior shoulder instability episodes. Click here to read the article.
Welcome to the first episode in this week's triple-header of late-breaking clinical trial coverage from Heart Rhythm 2026 in Chicago. In this episode Melissa E. Middeldorp, MPH, PhD from the Digital Education Committee sits down with David H. Birnie, MD and T. Jared Bunch, MD, FHRS to talk through this exciting late breaker. This late-breaking substudy of the ALONE-AF trial presented at Heart Rhythm 2026 evaluated whether discontinuing oral anticoagulation (OAC) after successful atrial fibrillation ablation impacts cognitive function in patients without long-term recurrence. The findings suggest that stopping OAC approximately one year post-ablation does not adversely affect cognitive outcomes, with cognitive scores improving similarly in both discontinuation and continuation groups among patients who remained arrhythmia-free. These results support the potential safety of OAC discontinuation in selected patients, while addressing an important gap in post-ablation management. Learning Objectives Understand the clinical rationale and current uncertainty surrounding continuation versus discontinuation of oral anticoagulation after successful AF ablation. Evaluate the impact of anticoagulation discontinuation on cognitive function in patients without recurrent atrial fibrillation. Apply emerging evidence from ALONE-AF and related studies to inform individualized decision-making on long-term anticoagulation management post-ablation. Podcast Contributors Melissa E. Middeldorp, MPH, PhD David H. Birnie, MD T. Jared Bunch, MD, FHRS Contributor Information: M. Middeldorp Nothing to disclose. D. Birnie Nothing to disclose. T.J. Bunch • Honoraria/Speaking/Teaching/Consulting: Heart Rhythm Society, Pfizer
In this episode, Eric and Jeff hang out with Perry Maughmer—a returning guest and one of their all-time favorite people—for an honest, practical (and sometimes funny) discussion about what it really means to grow as a person and a leader.What's Inside This Episode?Perry's New Book: Why He Wrote It for Himself - Perry tells us all about his newest book, The Recurrence Effect. But get this—he wrote it for himself first, doesn't care if it sells, and purposely didn't jam it with easy answers. His goal? Help you realize you have what you need already inside, even if that means sitting with the messy stuff and more ambiguity than you're used to.Why Copying Someone Else's Life Hacks Never Works - Ever get sucked into those “guaranteed” success frameworks online? Perry has zero time for that. He explains that just because a system or trick worked for one person doesn't mean it'll fit you. It's like wearing someone else's custom suit—a weird fit at best!Leadership: It's a Doing Thing, Not a Title - There's a super cool take here—Perry doesn't think “leader” should be a title. It should be about what you do, not who you are. The best leaders care about people, not KPIs. Results follow from that—not the other way around!How Companies Get People Development Wrong - Why do so many places take their top performer and make them a manager? Spoiler: it almost never works out how they hope. There's some real talk about how real people development takes YEARS of intentional change. No overnight hacks here.Curiosity vs. Judgment (and Why Saying "I Don't Know" Rocks) - Perry drops wisdom about choosing curiosity over judgment at work. Admitting you don't know everything actually makes you a better teammate and leader. Seriously—being curious opens up so many more possibilities.AI Is Eating Up Technical Skills—Now What? - Worried robots are taking your job? Perry says the real winners will be people who love to learn, not just people with mad technical skills. The key is staying adaptable and being comfortable with change and surprise.The Real Treasure is Inside - All the themes circle back to one core idea: stop forever searching for solutions outside yourself. Take ownership, look inward (even if it's scary), and realize you have what you need to keep growing and leading. It's not a quick fix, but it's more real.Real Moments & LaughsKicking off with some Bigfoot and Canadian toque jokesHonest opinions about why editing a book is “horrendous” and marketing can feel fakeWhy company learning should be voluntary and nobody should get dinged for “opting out”Featured Book:The Recurrence Effect by Perry Maughmer – Find it on Amazon and wherever you get your books.Get More from Perry:Podcast (he's starting it up again—no set routine, just genuine thoughts when he has them)Substack newsletter: “Inside the Return”Join the Conversation!Had any “aha!” moments? Ever felt like you were supposed to have life all figured out—when you really just needed some new questions? We want to hear from you:Have you ever chased outside answers when you maybe needed to look inside?How are you handling all the changes with tech and work?In each episode, Jeff and Eric will talk about what emotional intelligence, or understanding your emotions, can do for you in your daily and work life. For more information, contact Eric or Jeff at info@spiritofeq.com, or go to their website, Spirit of EQ.You can follow The Spirit of EQ Podcast on Apple Podcasts, Android, or on your favorite podcast player.New episodes are available on the 2nd and 4th Wednesdays every month!Please review our podcast on iTunes. Click on the link for an easy, step-by-step tutorial.Music from Uppbeathttps://uppbeat.io/t/roo-walker/deeperLicense code: PEYKDJHQNGSZXDUEhttps://creativecommons.org/licenses/by-nd/4.0/We hope you enjoy the podcast. Hopefully, you're tuning in on a regular basis. We'd love it if you would give us a great review on whatever platform you're listening to the podcast. It's so appreciative and helps us as we try to get more exposure for the work we do and the episodes that we publish. We're grateful to you as a listener. Secondly, our content is for educational purposes only. It's not intended by any stretch to diagnose or treat anything that may be occurring in your life or anyone else's life that you may be connected to through the podcast. And as always, we look forward to the next time that we're together. Take care.Spirit of EQMentioned in this episode:Thanks for listening to Spirit of EQThis podcast was created to be a tool to primarily help you to discover and grow your EQ. Science and our own lived experiences confirm that the better we are at managing our emotions, the better we're going to be at making decisions. Which leads to a better life. And that's something we all want. We're glad that you've taken the time today to listen. We hope that something you hear will lead to a breakthrough. We'd really appreciate a review on your podcast platform. Please leave some comments about what you heard today, as well as follow and subscribe to the podcast. That way, you won't miss a single episode as we continue this journey.
Our episode discussion includes comparing different Popemobiles (thanks Sheldon for the Pope fun fact!), what we would have done if we were Leonard, the bullying situations at our own schools, a better solution than letting Jimmy sleep on the couch, and more!Download hereRunning time: 1:22:35, 59.6 MB
Are you confident in identifying the risk for recurrence in early-stage HR-positive, HER2-negative breast cancer? Credit available for this activity expires: [04/21/27] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3?ecd=bdc_podcast_libsyn_mscpedu
In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Shengwen Calvin Li and Hrishi Krishna Srinagesh on their latest articles published in Blood. Dr. Li discusses "Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21". The study identifies reproducible abnormalities in progenitor expansion and increased apoptosis of polyploid megakaryocytes, and they propose a novel mechanism in which centrosomal over-expression of ANKRD26 drives polyploid megakaryocyte apoptosis through JUNB-mediated induction of p21 transcription. Dr. Srinagesh discusses "Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL" in which data collected by the Real-World Outcomes Collaborative of CAR-T in Adult ALL consortium showed that prior nonresponse to blinatumomab was associated with inferior survival after brexucabtagene in comparison to blinatumomab-naïve patients. Early CAR-T responses were uniformly high regardless of prior exposure or response. This highlights that resistance to blinatumomab may identify patients at higher risk of post–CAR T relapse despite excellent initial responses.
Sponsor-Stark Real-estate-[https://www.starkrealestatemi.com/](https://www.starkrealestatemi.com/)Get Episodes early-https://www.patreon.com/cw/TheMetalManiacsPodcast Welcome back to Metal Maniacs, hosted by Jay Ingersoll and Modd. In the 26th installment of our Reaction Series, we dive into a stacked batch of underground heavy music—alt metal, melodic metalcore, modern metalcore, groove metal, hard rock/metal, sludge/doom, and more.This episode features reactions to:Absent Light Arena — a two-piece project working between Australia & Sweden, blending atmospheric alt metal and melodic metalcore with cinematic electronics (debut album Fear, Doubt and Disbelief).Recurrence — heavy Michigan-adjacent heat with the album Art of Survival featuring guest talent including Björn “Speed” Strid (Soilwork), Peter Wichers (ex-Soilwork), and Per Nilsson (Scar Symmetry).Elijah Kinney — Detroit-area bassist/solo artist bringing sharp modern heavy songwriting and production (including “S.O.S” and the upcoming EP War of Submission).Mortal Draw — brand new band from Northwest Indiana dropping their first release.Terror Garden — Long Island hard rock/metal with “Supermodel Virus” and a new EP on the horizon.Devilz By Definition — groove metal for fans of Lamb of God, Pantera, Machine Head, including the intense “Angel Warfare.”Sod The Earth — Grand Rapids “dadcore” sludge/doom with Enter The Den (yes, it's as unhinged as it sounds).Xemaulc'tha — dark, story-driven heavy metal with “She Walks at Night” (feat. Rikk Hernandez).If you're into discovering new metal bands, underground metalcore, and heavy music that doesn't sound like everyone else—this one's for you.Like, subscribe/follow, and drop a comment telling us which band you want us to feature next.Band LinksAbsent Light Arena: Spotify | YouTube | Instagram | LinktreeRecurrence: Art of Survival (Spotify) | “Remember Who the Enemy Is” (YouTube) | About | Website | YouTube | LinktreeElijah Kinney: Website | YouTube | “S.O.S” Lyric VideoMortal Draw: Linktree | YouTubeTerror Garden: “Supermodel Virus” (Official Video) | LinktreeDevilz By Definition: Website | YouTube | SpotifySod The Earth: Instagram | Enter The Den (Spotify) | “The 10th Frame” (Spotify)Xemaulc'tha: “She Walks at Night” (YouTube) | Spotify | Apple MusicFollow Us-https://linktr.ee/metalmaniacsmi
In this new episode of Speaking of SurgOnc, Dr. Rick Greene & Dr. Mohammed Farooq discuss the article "Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy", from the January 2026 issue of the Annals of Surgical Oncology.
Manoj Monga explores the evolving understanding of kidney stone pathophysiology, from metabolic drivers to recurrence risk. This episode unpacks how clinicians balance acute intervention with long-term prevention strategies. Timestamps: 00:00 – Monga's background 02:30 – Pathophysiology explained 05:10 – Recurrence risk factors 08:20 – Dietary management 11:00 – Prevention versus surgery
Theoretical Nonsense: The Big Bang Theory Watch-a-Long, No PHD Necessary
Check out our recap and breakdown of Season 5 Episode 11 of the Big Bang Theory! We found 4 IQ Points!00:00:00 - Intro00:22:26 - Recap Begins00:23:12 - Honorary members of the Harlem Globetrotters00:38:37 - The Newcomb Medal01:02:41 - Is the fashion industry ruining our environment? 01:20:25 - Trespassing LawsFind us everywhere at: https://linktr.ee/theoreticalnonsense~~*CLICK THE LINK TO SEE OUR IQ POINT HISTORY TOO! *~~-------------------------------------------------Welcome to Theoretical Nonsense! If you're looking for a Big Bang Theory rewatch podcast blended with How Stuff Works, this is the podcast for you! Hang out with Rob and Ryan where they watch each episode of The Big Bang Theory and break it down scene by scene, and fact by fact, and no spoilers! Ever wonder if the random information Sheldon says is true? We do the research and find out! Is curry a natural laxative, what's the story behind going postal, are fish night lights real? Watch the show with us every other week and join in on the discussion! Email us at theoreticalnonsensepod@gmail.com and we'll read your letter to us on the show! Even if it's bad! :) Music by Alex Grohl. Find official podcast on Apple and Spotify https://podcasts.apple.com/us/podcast/theoretical-nonsense-the-big-bang-theory-watch-a/id1623079414
The literature suggests that both arthroscopic posterior Bankart repair (APB) and posterior bone block (PBB) are effective procedures in the short to medium term, although recurrence and revision rates do not appear to be negligible. However, fewer studies, especially comparative ones, are available regarding the long-term outcomes of these procedures. In conclusion, at a mean follow-up of 5 years for APB and 12 years for PBB, the APB group had a similar recurrence rate but fewer complications and revisions compared with the PBB group. Both techniques resulted in good to excellent clinical and functional outcomes, as well as high satisfaction and RTS rates. Click here to read the article.
Join Digital Education Committee member and podcast host Melissa E. Middeldorp, MPH, PhD, along with this week's guest contributors,Sheldon Litwin, MD from the Medical University of South Carolina and Abhishek Deshmuckh, MBBS from the Mayo Clinic for this week's episode. This real-world retrospective cohort study evaluated whether glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy is associated with improved outcomes after atrial fibrillation (AF) ablation in obese patients using a large multicenter electronic health record database (TriNetX). After propensity matching 6,700 patients (3,350 GLP-1RA users and 3,350 non-users), GLP-1RA therapy was associated with significantly lower AF recurrence, progression to permanent AF, cardiovascular and heart failure hospitalizations, and all-cause mortality over a median ~2-year follow-up, although repeat ablation rates were unchanged. The authors propose that benefits may be mediated through weight-loss, reduction in systemic inflammation and epicardial fat, improved metabolic control, and potential direct atrial effects, but emphasize that causal inference is limited due to observational design and lack of weight-loss trajectory or adherence data. Overall, the study suggests GLP-1RAs could become an adjunct rhythm-control strategy in obese AF patients undergoing ablation, warranting prospective randomized trials. Learning Objectives Understand the association between GLP-1 RA therapy and reduced AF recurrence and cardiovascular outcomes after catheter ablation in obese patients. Evaluate the potential mechanisms and clinical implications of GLP-1 RAs as an adjunctive metabolic therapy in rhythm control strategies for AF. Article for Discussion Article Authors Sandrine Venier, Pascal Defaye, Lisa Lochon, Rémi Benali, Arnaud Bisson, Adrien Carabelli, Youssou Diouf, Peggy Jacon, Laurent Fauchier Podcast Contributors Melissa E. Middeldorp, MPH, PhD Abhishek Deshmuckh, MBBS Sheldon Litwin, MD Host and Contributor Disclosure(s): M. Middeldorp Nothing to disclose. A. Deshmukh •Honoraria/Teaching/Speaking/Consulting: GE Healthcare S. Litwin Honoraria/Teaching/Speaking/Consulting: Axon Therapies, Novo Nordisk, Alleviant, Corvia Medical Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.
In this episode, we break down a major factor in treating SIBO and preventing recurrence: biofilm disruption. You'll learn how to identify the telltale signs of biofilms, the steps to our proven treatment protocol, and discover the dietary and supplement strategies that support lasting gut recovery. Our approach is backed by our recently published study, Biofilm Disruption Enhances Antimicrobial Therapy for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth. Read the full findings here:https://pubmed.ncbi.nlm.nih.gov/41394228/. If you've struggled with recurring SIBO and felt like nothing works, this episode will guide you to effective solutions.
In this heartfelt episode of The Summits Podcast, cohosts Vince Todd, Jr. and Daniel Abdallah sit down with twin sisters Liz Childers and Norma Unser to share an inspiring and deeply personal conversation about their family's journey with cancer. Liz and Norma open up about how cancer has profoundly impacted their lives, with their mom, Liz, and Norma all facing breast cancer diagnoses. They discuss the emotional and physical challenges of their battles, the critical role of routine screenings in early detection, and the strength they've found in each other. The conversation also highlights the groundbreaking work of the Cancer Vaccine Coalition and the hope it brings for the future of cancer outcomes and prevention. Liz and Norma's story is a powerful reminder of resilience, the importance of advocacy, and the strides being made in the fight against cancer. Learn more about the Cancer Vaccine Coalition: https://cancervaccinecoalition.org/ Shop Lizzie Lu's Crew hats! https://lizzielucrew.com/
Commentary by Dr. Jian'an Wang
Commentary by Dr. Takeshi Aiba
In episode 617, Tina and James bring in Caitlin Finley to review the latest trial that attempts to answer the question of does treating male sexual partners of females undergoing treatment for bacterial vaginosis infection decrease recurrence? We'll find out that despite this trial getting lots of press it doesn't provide definitive evidence about who/how […]
In this JCO Precision Oncology Article Insights episode, host Dr. Carolyn Lineen summaries the article, "Concordance of Oncotype DX Breast Recurrence Score Assay Results Between Paired Core Needle Biopsy and Surgical Excision Specimens in Hormone Receptor Positive, HER2-Negative Early-Stage Breast Cancer," by Nassar et al. TRANSCRIPT Carolyn Lineen: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host, Carolyn Lineen, from St. James's Hospital, Dublin, and today we will be discussing the JCO Precision Oncology article titled "Concordance of Oncotype DX Breast Recurrence Score Assay Results Between Paired Core Needle Biopsy and Surgical Excision Specimens in Hormone Receptor Positive, HER2-Negative Early-Stage Breast Cancer" by Dr. Aziza Nassar and colleagues. The Oncotype DX Breast Recurrence Score assay is a 21-gene expression test that provides both prognostic information regarding distant recurrence risk and predictive information regarding the benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative early-stage breast cancer. The recurrence score ranges from 0 to 100, with higher scores indicating a greater risk of recurrence and a potentially higher likelihood of benefit from chemotherapy. Traditionally, genomic testing is performed on surgical excision specimens following tumor resection. However, this approach can potentially delay access to biological risk stratification, which may be important when early treatment planning or neoadjuvant therapy is being considered. The primary objective of this study was to evaluate the level of concordance between recurrence scores derived from paired core needle biopsy specimens and surgical excision specimens obtained from the same untreated primary breast tumors. Investigators specifically evaluated both continuous recurrence score agreement and categorical risk classification concordance. The study included 134 patients with paired biopsy and surgical specimens. The median patient age was 62 years, with a wide age range from 33 to 99 years. Approximately 17% of patients were aged 50 years or younger, while 83% were older than 50 years. All patients had hormone receptor-positive, HER2-negative early-stage breast cancer and had not received prior systemic treatment before either specimen collection. Each patient contributed two tumor samples: a core needle biopsy specimen obtained at initial diagnosis and a surgical excision specimen obtained during definitive tumor resection. Both samples underwent Oncotype DX testing, allowing direct within-patient comparison. The investigators reported mean recurrence scores of 15.6 for core needle biopsy specimens and 16.6 for surgical excision specimens. Although this absolute mean difference between specimen types did reach statistical significance with a P value of 0.003, the authors note that this numerical difference was small at one recurrence score unit and may not therefore be clinically meaningful. Additionally, categorical recurrence score results did not differ significantly. The primary measure of agreement between recurrence scores was the Lin's concordance correlation coefficient. The study demonstrated a Lin concordance correlation coefficient of 0.86 with a 95% confidence interval ranging from 0.80 to 0.90, indicating strong agreement between biopsy and surgical specimens. Additionally, categorical agreement was assessed using Cohen's kappa statistic. The study reported a kappa value of 0.64 with a 95% confidence interval from 0.44 to 0.83, indicating substantial agreement between specimen types. Comparing this study to previously published evidence, the authors referenced prior smaller studies examining concordance between paired tissue samples. For example, earlier research evaluating 50 patients demonstrated correlation coefficients of approximately 0.8 and categorical concordance rates ranging from 72% to 78%, depending on the classification cut points used. Compared with earlier studies, the present study provides stronger evidence supporting consistency between biopsy and surgical testing. These findings have several important implications for clinical practice. First, early availability of recurrence score results may enhance multidisciplinary care planning. Obtaining genomic risk data at the time of diagnosis allows tumor boards to integrate molecular risk stratification into initial treatment discussions rather than waiting for postoperative results. Second, biopsy-based testing may support decision making regarding treatment sequencing. Earlier genomic information may help guide selection of neoadjuvant therapy or inform early decisions about adjuvant chemotherapy necessity. Third, early testing may reduce delays in treatment initiation. Separate research evaluating presurgical Oncotype DX testing has demonstrated potential reductions in time to initiation of adjuvant therapy by approximately 8 days, suggesting potential improvements in care efficiency. Additionally, biopsy-based testing demonstrates strong technical feasibility. Studies examining real-world implementation have reported test success rates as high as 99.1% when performed on core biopsy specimens. Despite the encouraging results, certain limitations must be considered. Core needle biopsy samples evaluate only a portion of the tumor, and intratumoral heterogeneity could theoretically influence recurrence score results in selected cases. Preanalytical factors, including tissue fixation and sample handling, may also affect RNA integrity and assay performance. Standardization of specimen processing protocols will be essential if biopsy-based testing becomes routine. Furthermore, although analytical concordance is strong, prospective outcome studies demonstrating equivalent long-term clinical outcomes based on biopsy-directed treatment decisions would further strengthen the evidence base. In conclusion, this study demonstrates strong concordance between Oncotype DX Breast Recurrence Scores derived from core needle biopsy specimens and surgical excision specimens in patients with hormone receptor-positive, HER2-negative early-stage breast cancer. With a concordance correlation coefficient of 0.86 and overall categorical agreement exceeding 90%, the findings support the clinical feasibility of performing genomic testing at the time of diagnostic biopsy. If validated through additional prospective studies, this approach may enable earlier risk stratification and improve multidisciplinary treatment planning. Thank you for tuning in to JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
The high rates of failures and reoperations (up to 50%) after arthroscopic posterior Bankart repair (APBR) remain a concern. In conclusion, in patients with recurrent posterior instability, the presence of posterior glenoid erosion was the main risk factor for failure after APBR. By contrast, a posterior bony Bankart lesion did not represent a contraindication to arthroscopic stabilization using suture anchor fixation. Click here to read the article.
Love the episode? Send us a text!What happens when a breast surgeon becomes a breast cancer patient—and then faces a second diagnosis years later?In this deeply personal and illuminating episode of Breast Cancer Conversations, host Laura Carfang is joined by Dr. Anne Peled, a board-certified breast, reconstructive, and plastic surgeon who has treated thousands of patients—and also navigated her own early-stage breast cancer diagnosis, followed years later by a new primary DCIS diagnosis.Together, Laura and Dr. Peled unpack what patients are rarely told about DCIS (stage zero breast cancer), the difference between recurrence and a second primary cancer, and how advances in surgery are transforming survivorship—including sensation-preserving mastectomy.This conversation bridges clinical expertise and lived experience, offering clarity, compassion, and permission to choose the path that aligns with your body and values.In this episode: What DCIS really is—and why “stage zero” can be misleadingRecurrence vs. second primary breast cancer: why biology mattersLumpectomy vs. mastectomy and why survival outcomes are often the sameHow guilt and self-blame show up after a second diagnosisBeing diagnosed with breast cancer as a physicianNavigating treatment when your colleagues are your caregiversThe evolution of oncoplastic surgery and patient-centered careWhy loss of breast sensation is under-discussed—but life-changingHow sensation-preserving mastectomy worksWhat questions to ask your surgeon about sensation, nerves, and recoveryMaking decisions based on your priorities—not fear or pressureAbout today's guestDr. Anne Peled is a board-certified plastic, reconstructive, and breast surgeon in private practice in San Francisco and Co-Director of the Sutter Health California Pacific Medical Center Breast Cancer Center of Excellence. Trained at Amherst College, Harvard Medical School, and UCSF, Dr. Peled completed a unique fellowship combining breast oncologic surgery and reconstruction.Her clinical and research work focuses on oncoplastic surgery, preserving and restoring sensation after mastectomy, improving patient outcomes, and breast cancer risk reduction. She is also a breast cancer survivor herself, bringing rare dual insight to patient care. Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources! Enjoying our content? Please consider supporting our work.
Discover the powerful connection between weight loss, exercise, and cancer risk. Dr. Lisa Oldson breaks down the latest research showing how intentional weight loss, whether through lifestyle changes, GLP-1 medications, or bariatric surgery, can significantly reduce your risk of 13 different types of cancer. Learn why exercise is one of the most effective tools for both preventing cancer and improving outcomes after diagnosis, with reductions in recurrence rates of up to 48%. This episode empowers you with five actionable strategies you can implement today to lower your cancer risk and lengthen your health span.Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.
In episode 520 astrologer Nick Dagan Best joins me for a live workshop where we interviewed five listeners who shared stories about how recurrence transits coincided with important moments in their lives. This is a follow-up to our original episode on recurrence transits from November 2025, where we first introduced the concept of tracking when planetary aspects in the sky repeat specific aspect configurations from your birth chart. While our initial discussion focused largely on celebrity charts to illustrate the theory, for this episode we wanted to demonstrate how this technique manifests in practice by interviewing several patrons who generously shared their personal stories. During the show, we speak with five listeners who walk us through their chronologies to show how these transits coincided with major life events. We examine a wide variety of planetary combinations, including Mars-Saturn, Mars-Uranus, and Venus-Jupiter alignments. The examples illustrate how the repetition of a natal aspect can trigger pivotal turning points involving career changes, relationships, accidents, and even multi-generational family patterns. What becomes clear through these interviews is how the recurrence of a natal aspect often coincides with events that are thematically consistent with the original promise of the birth chart, sometimes playing out as literal repetitions of the past or as significant evolutions of a personal narrative. We also discuss some of the technical nuances of working with recurrence transits, such as the importance of phase relationships, and how to track these cycles using the search tools available on Astro-Seek. This episode serves as a practical demonstration of how to research and apply this technique to gain a deeper understanding of your own biography and the timing of major life events. Nick's Website https://www.nickdaganbestastrologer.com Timestamps 00:00:00 Introduction00:04:48 How to look up recurrence transits in your chart00:12:58 Ginger: Mars-Saturn Recurrence00:34:34 Jacqueline: Venus-Jupiter & Mars-Saturn Recurrences01:01:44 Karen: Jupiter trine Uranus Recurrence01:12:04 Lauren: Venus-Mars and Mars-Saturn Squares01:32:41 Connie: Venus-Jupiter Square Recurrence01:48:07 Q&A and Final Thoughts01:56:03 Credits Watch the Video Version of This Episode https://www.youtube.com/watch?v=cPCr7-e8vtI - Listen to the Audio Version of This Episode Listen to the audio version of this episode or download it as an MP3:
For people who've had colorectal cancer, celecoxib, a commonly prescribed medicine for pain, may help avoid disease recurrence, a recent analysis of a larger study found. Kimmel Cancer Center director William Nelson at Johns Hopkins explains that the presence of … Can the drug celecoxib help some people avoid colorectal cancer recurrence? Elizabeth Tracey reports Read More »
Love the episode? Send us a text!What happens when breast cancer comes back — even after doing “everything right”?In this deeply honest conversation, Laura Carfang sits down with Teresa Baglietto, a four-time cancer survivor, author, and podcast host, to talk about what it really means to live with cancer recurrence, fear, and long-term survivorship.Teresa shares what it felt like to discover her first breast cancer lump (“it was like a block of cement”), how she navigated a recurrence after bilateral mastectomy, and the treatment decisions that ultimately saved her life — including why she chose not to take chemotherapy or tamoxifen.Together, Laura and Teresa explore the emotional and practical realities of survivorship: fear of recurrence, making medical decisions without complete information, balancing career and health, and finding purpose after cancer.This episode is for anyone newly diagnosed, living with metastatic or recurrent disease, or learning how to live after cancer — when the world expects you to “move on,” but your body and mind remember everything.In This Episode, We Talk About:What a breast cancer lump can actually feel likeBeing diagnosed after delaying a mammogramBreast cancer recurrence after mastectomyRadiation vs chemotherapy and treatment decision-makingOncotype DX testing and personalized careSaying no to tamoxifen after severe side effectsFear of recurrence and how it shows up years laterHow cancer reshapes career, identity, and purposeWhy having a plan can help you survive the unknownFinding meaning and community after diagnosisAbout Our GuestTeresa Baglietto is a four-time cancer survivor, author of The Ripple Effect, and host of the podcast InShok. Her work focuses on resilience, leadership, and navigating life's hardest moments with intention and courage.Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources! Enjoying our content? Please consider supporting our work.
In this week's episode we've pulled a vault recording from 2025! Blood editor Dr. Laurie Sehn interviews authors Drs. David-Alexandre Trégouët and Johannes Schetelig on their research published in volume 146 issue 19 of Blood journal. Dr. Trégouët's study conducted a genome-wide association study supplemented by transcriptome and Mendelian randomization analyses to identify 28 loci and proteins associated with VTE recurrence risk. This work provides genomic evidence that inherited variants contribute to the risk of VTE recurrence, raising the possibility of a more personalized approach to the prevention of recurrent VTE. The study conducted by Dr. Schetelig and colleagues report the results of a long term trial on patients with poor-response AML, comparing outcomes between patients who received salvage chemotherapy versus immediate transplantation. With no difference in survival rates at 5 years, outcomes seem to be determined mainly by genetic risk factors, age, and comorbidities, therefore challenging the routine use of intensive remission induction before allogeneic transplant in patients with an available donor and underscore the need for novel therapeutic strategies for poor-risk AML.Featured Articles:Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial
The Peaceful Plate: Ending Food Panic After Hormone-Driven Breast Cancer
So many women finish treatment for hormone-driven breast cancer and struggle to navigate their alcohol consumption; it causes so much angst! In today's episode I highlight the connection between alcohol and recurrence risk and guide you through an exercise in decision-making about your own approach to alcohol. If you feel guilty about your nightly wine or weekend martini habit, this is the episode for you! Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here!Follow me on Instagram @hormone.breastcancer.dietitian
At the 2025 San Antonio Breast Cancer Symposium, Megan-Claire Chase, known online as Warrior Megsie, a fierce and funny breast cancer advocate, presented a poster on real-world patient and caregiver experiences with breast cancer risk of recurrence in the United States. Listen to the episode to hear Megan-Claire explain: why she and her colleagues wanted to do the survey the gaps in survivorship care the survey uncovered the support services patients and caregivers need
An L.A. based podcast brought to you by two forensic psychologists who dissect the intersections where true crime, forensic psychology, and entertainment meet. Episode Description: Crazy In Love: Erotomania Dr. Scott & Dr. Shiloh get into the subcategory of Delusional Disorder, Erotomania; to have the delusional or false belief of a secret or known admirer. This disorder is often the trigger for obsessive celebrity stalkers and has been the cause for numerous violent acts. The docs explore the origin, criteria, and research of this rare phenomenon and cover the cases of John Hinkley Jr., Margaret Mary Ray, and the shooter who killed rising star Christina Grimmie. Related episode: Stalking: The Crime of the 90's https://anchor.fm/lansc/episodes/25--Stalking-The-Crime-of-the-90s-e537ff Donate to the Christina Grimmie Foundation here: https://christinagrimmiefoundation.org/ Mentions: Lenora Consulting LLC https://www.lenoraclairellc.com/ 10ish Podcast https://www.10ishpod.com/ Resources Braun, Claude, and Sabrina Suffren. "A General Neuropsychological Model of Delusion." ResearchGate, Taylor & Francis (Routledge), Mar. 2010, www.researchgate.net/publication/41670340_A_general_neuropsychological_model_of_delusion. Accessed 26 Nov. 2021. Brüne, Martin. "Erotomanic Stalking in Evolutionary Perspective." Behavioral Sciences & the Law, vol. 21, no. 1, 16 Dec. 2002, pp. 83–88, pubmed.ncbi.nlm.nih.gov/12579619/#:~:text=Erotomania%2C%20the%20delusion%20of%20being,concerning%20prevalence%20rates%20and%20behavior.&text=The%20evolutionary%20perspective%20may%20provide,understanding%20of%20forensically%20relevant%20behaviors., 10.1002/bsl.518. Accessed 26 Nov. 2021. Christina Grimmie: The Murder of a Rising Star. Orlando Sentinel, 4 June 2018, disc 1-2. Podcast. "De Clerambault Syndrome (Erotomania) in the Criminal Justice System: Another Look at This Recurring Problem | Office of Justice Programs." Ojp.gov, 2021, www.ojp.gov/ncjrs/virtual-library/abstracts/de-clerambault-syndrome-erotomania-criminal-justice-system-another. Accessed 26 Nov. 2021. Ghosh, Tulika, and Minkesh Chowdhary. De Clerambault Syndrome: Current Perspective. Www.intechopen.com, IntechOpen, 12 May 2021, www.intechopen.com/chapters/72361. Accessed 27 Nov. 2021. Hayes, Crystal. "Forgotten Story of Singer's Legacy, Man Who Killed Her." Courier-Post, 18 Dec. 2016, www.courierpostonline.com/story/news/local/south-jersey/2016/12/18/forgotten-story-christina-grimmie-and-man-who-killed-her/95585040/. He Loves Me, He Loves Me Not. Directed by Laetitia Colombani, Samuel Goldwyn Films, 2003. Harmon RB;Rosner R;Owens H. "Obsessional Harassment and Erotomania in a Criminal Court Population." Journal of Forensic Sciences, vol. 40, no. 2, 2011, pubmed.ncbi.nlm.nih.gov/7602275/. Accessed 26 Nov. 2021. "How History Changed Anita Hill (Published 2019)." The New York Times, 2021, www.nytimes.com/2019/06/17/us/anita-hill-women-power.html. Accessed 27 Nov. 2021. Jamaluddin, Ruzita. "Same Gender Erotomania: When the Psychiatrist Became the Delusional Theme—a Case Report and Literature Review." Case Reports in Psychiatry, vol. 2021, 1 Sept. 2021, p. e7463272, www.hindawi.com/journals/crips/2021/7463272/, 10.1155/2021/7463272. Kelly, B. D., et al. "Delusion and Desire: Erotomania Revisited." Acta Psychiatrica Scandinavica, vol. 102, no. 1, July 2000, pp. 74–76, pubmed.ncbi.nlm.nih.gov/10892614/, 10.1034/j.1600-0447.2000.102001074.x. Accessed 26 Nov. 2021. Meloy, J. CASE REPORT Erotomania, Triangulation, and Homicide. "Risk Factors for Stalking Violence, Persistence, and Recurrence." The Journal of Forensic Psychiatry & Psychology, 2017, www.tandfonline.com/doi/abs/10.1080/14789949.2016.1247188?journalCode=rjfp20&. Accessed 26 Nov. 2021. Safeekh, AT, and Denzil Pinto. "Venlafaxine-Induced Psychotic Symptoms." Indian Journal of Psychiatry, vol. 51, no. 4, 2009, p. 308, www.ncbi.nlm.nih.gov/pmc/articles/PMC2802382/, 10.4103/0019-5545.58301. Accessed 26 Nov. 2021. Sederholm, Jillian. "Gunman Who Killed 'the Voice' Singer Had Extra Ammo, Knife: Police." NBC News, 11 June 2016, www.nbcnews.com/news/us-news/voice-singer-christina-grimmie-shot-after-florida-concert-n590161. Accessed 27 Nov. 2021. Shanee Edwards. "I Just Discovered the Crazy World of Erotomania Thanks to HBO's Confirmation." SheKnows, SheKnows, 17 Apr. 2016, www.sheknows.com/entertainment/articles/1119045/erotomania-and-confirmation-hbo/. Accessed 26 Nov. 2021.
An introduction to an obscure but powerful timing technique called recurrence transits, which occur when specific planetary alignments in the birth chart are repeated by transits in the sky, with astrologers Chris Brennan and Nick Dagan Best. Unlike standard transits that form aspects to specific points in the natal chart, a recurrence transit occurs when a planetary alignment found in a birth chart repeats in the sky between those same two planets. For example, if a person was born with a Venus-Jupiter conjunction in their birth chart, then an important event will happen in their life in the future when Venus and Jupiter again form a conjunction in the sky. The episode uses the analogy that specific planetary alignments in the birth chart act like a personal theme song; when the planets repeat the same alignment in the sky, it is as if that music starts playing again, signaling a pivotal turning point where the natal potential of the birth signature becomes awakened through a resonance between past and future. The episode opens by exploring the history and transmission of the technique, which is relatively unknown in the English-speaking world at the present time. Nick shares how he learned the method from the late Michael Lutin in the 1990s, while Chris traces potential roots back to early 20th-century German astrology and ancient Hellenistic texts like Vettius Valens. A key point emphasized early on is how these mundane planetary recurrences operate independently of aspects to natal placements, forcing a conceptual expansion of what defines a transit, and demonstrating how planetary cycles can be tied into important turning points in a life narrative even without direct contact with birth chart placements. To demonstrate the technique in practice, most of the episode is spent presenting a wide range of biographical examples as case studies, and focusing primarily on conjunctions in order to keep things simple and compelling. Case studies include the technological breakthroughs of Steve Jobs and Max Planck, the artistic peaks of Vincent van Gogh and Madonna, and the political rises and falls of figures like Richard Nixon and Joe Biden. The workshop also examines how retrogrades can both extend and intensify the importance of certain recurrence transits, as seen in the lives of Edward Snowden and Charles Manson, and we also touch on shared recurrences in relationships, such as Kurt Cobain and Courtney Love. The conversation concludes with a broader philosophical discussion on what this technique implies about the nature of astrology, touching on concepts like simulation theory and the definition of astrology as a map of time. This episode serves as a comprehensive foundation for understanding recurrence transits, providing astrologers and students with a powerful, empirically driven tool for predictive work and biographical analysis that complements traditional methods. This is episode 513 of The Astrology Podcast. Nick's Website https://www.nickdaganbestastrologer.com Bonus Episode for Patrons If you enjoy this episode and are looking for more, we recorded a followup episode on recurrence transits which is available to subscribers on Patreon: https://www.patreon.com/posts/secret-astrology-143901212 In the followup episode we share 16 more chart examples that didn't make it into the main episode, which allows us to go into some planetary combinations that we didn't cover previously, and also cover some new facets of the technique such as multiple planet recurrences and intergenerational recurrences. Timestamps 00:00:00 Introduction00:10:49 History and origins of the technique00:20:42 The technique in Vettius Valens00:24:55 Michael Lutin00:29:11 Chris coming around to the technique00:40:39 Focusing on conjunctions00:42:52 USA Mars-Uranus conjunction00:54:28 Natal examples segment begins00:54:48 Chaz Bono00:58:02 Retrograde stations heighten importance00:59:21 Vincent van Gogh01:09:42 Max Planck (Jupiter-Uranus)01:13:22 Steve Jobs (Jupiter-Uranus)01:25:56 Chris' chart01:46:40 Rock Hudson (Mars-Saturn)01:52:03 Malcolm X (Mars-Pluto)01:56:49 Kurt Cobain & Courtney Love (Venus-Saturn & Venus-Mars)02:05:01 Charlie Kirk & Zohran Mamdani (Mercury-Mars)02:11:33 Edward Snowden (Mercury-Mars)02:18:54 Venus Williams (Mars-Saturn)02:25:23 Jada Pinkett Smith (Jupiter-Neptune)02:32:10 Amelia Earhart (Mars-Jupiter)02:34:25 Richard Nixon (Mars-Jupiter)02:45:13 Joe Biden (Saturn-Uranus)02:56:41 The Beatles (Saturn-Uranus)03:10:59 Michael Jackson (Jupiter-Neptune)03:20:32 Madonna (Jupiter-Neptune)03:29:05 Charles Manson (Mars-Neptune)03:42:19 Prince Harry and Meghan Markle (Saturn-Pluto)03:52:38 Beyonce (Jupiter-Saturn)03:59:44 Reflecting on the technique04:04:34 Secret Astrology Podcast follow-up04:09:28 Lessons learned and concluding remarks04:28:35 Simulation Theory04:36:35 Astrology as a map of time04:41:54 Credits Watch the Video Version of This Episode https://www.youtube.com/watch?v=GG0Il1QZkmU – Listen to the Audio Version of This Episode Listen to the audio version of this episode or download it as an MP3:
Interview with Ann Brunson, MS, and Theresa H. M. Keegan, PhD, MS, authors of Metastatic Recurrence Among Adolescents and Young Adults With Cancer. Hosted by Vivek Subbiah, MD. Related Content: Metastatic Recurrence Among Adolescents and Young Adults With Cancer Metastatic Recurrence in Adolescent and Young Adult Cancer—Key Drivers of Early Mortality
Chanchal is a medical herbalist and has been in clinical practice since 1987 with a specialty in holistic oncology for over 20 years. She is the author of multiple books, with her latest titled, Holistic Cancer Care: An Herbal Approach to Preventing Cancer, Helping Patients Thrive during Treatment, and Minimizing the Risk of Recurrence. For over 10 years, she was faculty chair in Botanical Medicine at the Boucher Institute of Naturopathic Medicine in New Westminster and she publishes widely in professional journals and lectures internationally on medical herbalism, nutrition and health. Chanchal is also a certified Shinrin Yoku (forest bathing) practitioner, a certified Master Gardener and a certified Horticulture Therapist. Chanchal lives on Vancouver Island, British Columbia where she and her husband manage Innisfree Farm and Botanic Garden, a 7 acre internationally registered botanic garden specializing in food and medicine plants. The farm hosts Gardens without Borders, a federally registered not-for-profit society established to run the botanic garden and provide horticulture therapy. To connect with Chanchal: www.chanchalcabrera.com facebook.com/chanchal.cabrera instagram.com/chanchal.cabrera/ YouTube: @chanchal.cabrera ___________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook Instagram YouTube _______________ Why does Dr. Linda Isaacs, M.D., a board-certified internist, offer an enzyme-based nutritional program for cancer patients? Decades of seeing people have much better outcomes than expected. The approach she uses is not an easy answer and it's not a guarantee. It involves a lot of capsules and big lifestyle changes. But for the right patient, it can be transforming. For more information about her work, please visit her website at www.drlindai.com/radical You can also listen to her interview on the Radical Remission podcast: https://www.podbean.com/ew/pb-7v5kr-1546ad9
This Week in Machine Learning & Artificial Intelligence (AI) Podcast
Today, we're joined by Jacob Buckman, co-founder and CEO of Manifest AI to discuss achieving long context in transformers. We discuss the bottlenecks of scaling context length and recent techniques to overcome them, including windowed attention, grouped query attention, and latent space attention. We explore the idea of weight-state balance and the weight-state FLOP ratio as a way of reasoning about the optimality of compute architectures, and we dig into the Power Retention architecture, which blends the parallelization of attention with the linear scaling of recurrence and promises speedups of >10x during training and >100x during inference. We review Manifest AI's recent open source projects as well: Vidrial—a custom CUDA framework for building highly optimized GPU kernels in Python, and PowerCoder—a 3B-parameter coding model fine-tuned from StarCoder to use power retention. Our chat also covers the use of metrics like in-context learning curves and negative log likelihood to measure context utility, the implications of scaling laws, and the future of long context lengths in AI applications. The complete show notes for this episode can be found at https://twimlai.com/go/750.
Subscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsWhat happens when the “healthy one” gets cancer? Samantha Harris shares the diagnosis that changed everything.In this deeply moving episode of Hol+, Dr. Taz MD sits down with Emmy-nominated TV host, author, and breast cancer survivor Samantha Harris to unpack her harrowing and empowering health journey—from being blindsided by a breast cancer diagnosis at 40, to navigating a recurrence a decade later, despite living what she thought was the healthiest lifestyle.Best known as the radiant host of Dancing with the Stars and Entertainment Tonight, Samantha takes us behind the scenes of her transformation from fitness icon to fierce advocate, author, and functional health warrior. She opens up about her fight to be taken seriously by doctors, why mammograms failed to detect her cancer, and the powerful philosophy she developed in the aftermath: “10% Toxic.”This conversation is packed with raw honesty, actionable insights, and the kind of wisdom that only comes from walking through fire—twice.Samantha opens up about:How a “normal” mammogram nearly cost her everythingThe misdiagnosis that delayed her treatment for monthsHer decision to skip chemo and radiation—and why she still doesn't regret itThe power of intuition in healing and early detectionHow to build your “doctor squad” and advocate for yourselfHer 10% toxic philosophy to reduce overwhelm and reclaim wellnessHow she now supports women around the world through her book, podcast, and retreatsWhether you've faced cancer, know someone who has, or simply want to prevent disease in a world full of overwhelm, this episode offers real talk, real tools, and real hope.Connect further to hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+.About Samantha HarrisA 4-time Emmy Award nominee, she's best known for lighting up our screens for 8 unforgettable seasons as the host of Dancing with the Stars—and she also won the Emmy for her years on Entertainment Tonight! She's the only host to have ever anchored every major national entertainment news program from Access Hollywood and EXTRA to E! News and more.But behind the bright lights, life took an unexpected turn. At just 40 years old, this devoted wife and mom of two young daughters faced a shocking breast cancer diagnosis. A decade later, at 50, she was blindsided yet again by a recurrence. But Samantha Harris didn't just survive—she redefined what it means to thrive. She turned her journey into a mission—becoming a Certified Health Coach, and the bestselling author and dynamic host of the top-rated podcast, Your Healthiest Healthy. You've seen her as a trusted health expert on Good Morning America, FOX & Friends, The Doctors, HLN's Morning Express, and more—sharing practical, life-changing wellness strategies. As a National Ambassador for the world's largest breast cancer foundation, Susan G. Komen, she's on a mission to uplift, empower, and equip others to take control of their health like never before—one manageable step at a time.Stay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Connect with Samantha Harrishttps://samantha-harris.com/https://www.instagram.com/samanthaharristv/Host & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+Chapters00:00 Introduction02:43 Samantha's Health Journey Begins05:28 Navigating the Medical System07:21 Making Treatment Decisions15:38 Treatment Options and Outcomes31:32 Recovery and Genetic Testing32:54 The Journalist's Deep Dive into Breast Cancer34:15 Exercise and Lifestyle Changes36:03 Diet and Nutrition Misconceptions37:54 Balancing Career and Health40:27 The Recurrence and New Insights47:03 The 10% Toxic Philosophy50:06 Practical Tips for a Healthier Life01:02:48 Final Thoughts and Conclusion
© 2020-2026 Ivy Podcast Discovery LLC
